XTL Biopharmaceuticals to Present at the Jefferies Life Sciences Conference
June 26 2006 - 5:53AM
PR Newswire (US)
NEW YORK, June 26 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals,
Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced today that Ron
Bentsur, the Company's Chief Executive Officer, is scheduled to
present at the Jefferies Life Sciences Conference. Mr. Bentsur's
presentation will take place on Wednesday, June 28, 2006 at 10:45
am EDT at The Mandarin Oriental Hotel in New York City. A live
audio webcast of Mr. Bentsur's presentation will be available at
http://www.wsw.com/webcast/jeff11/xtlb/. An archived version of the
webcast will be available following the conclusion of the live
presentation. About XTL Biopharmaceuticals, Ltd. XTL
Biopharmaceuticals Ltd. ("XTLbio") is engaged in the acquisition,
development and commercialization of therapeutics for the treatment
of infectious diseases, with a focus on hepatitis C. XTLbio is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of
the hepatitis C virus polymerase. XTL-2125 is currently in a Phase
1 clinical trial in chronic hepatitis C patients. XTLbio is also
developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus - presently in Phase 1 clinical
trials in patients with chronic hepatitis C. XTLbio's hepatitis C
pipeline also includes several families of pre-clinical hepatitis C
small molecule inhibitors. In addition, XTLbio has out-licensed to
Cubist Pharmaceuticals an antibody therapeutic against hepatitis B,
HepeX-B, which has recently completed a Phase 2b clinical study in
hepatitis B liver transplant patients. XTLbio is publicly traded on
the NASDAQ, London, and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact: Ron Bentsur Chief
Executive Officer +1-(212)-531-5971 DATASOURCE: XTL
Biopharmaceuticals Ltd CONTACT: Contact: Ron Bentsur, Chief
Executive Officer, +1-(212)-531-5971,
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024